JP2021185199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021185199A5 JP2021185199A5 JP2021146086A JP2021146086A JP2021185199A5 JP 2021185199 A5 JP2021185199 A5 JP 2021185199A5 JP 2021146086 A JP2021146086 A JP 2021146086A JP 2021146086 A JP2021146086 A JP 2021146086A JP 2021185199 A5 JP2021185199 A5 JP 2021185199A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- angular positions
- deficiency
- disease
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 41
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 208000013200 Stress disease Diseases 0.000 claims 14
- 230000036542 oxidative stress Effects 0.000 claims 14
- 238000000634 powder X-ray diffraction Methods 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- -1 carrier Substances 0.000 claims 7
- 230000007812 deficiency Effects 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 208000006011 Stroke Diseases 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 206010011878 Deafness Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims 3
- 206010061323 Optic neuropathy Diseases 0.000 claims 3
- 239000000090 biomarker Substances 0.000 claims 3
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 230000010370 hearing loss Effects 0.000 claims 3
- 231100000888 hearing loss Toxicity 0.000 claims 3
- 208000016354 hearing loss disease Diseases 0.000 claims 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims 3
- 208000012268 mitochondrial disease Diseases 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 208000020911 optic nerve disease Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 206010058892 Carnitine deficiency Diseases 0.000 claims 2
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims 2
- 108700006159 Long-chain acyl-CoA dehydrogenase deficiency Proteins 0.000 claims 2
- 108700000232 Medium chain acyl CoA dehydrogenase deficiency Proteins 0.000 claims 2
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims 2
- 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 201000009623 Myopathy Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 201000007737 Retinal degeneration Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 230000001919 adrenal effect Effects 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims 2
- 208000004687 long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 2
- 208000005548 medium chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000003645 multiple acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims 2
- 201000010866 very long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 2
- 208000010444 Acidosis Diseases 0.000 claims 1
- 208000019932 Aciduria Diseases 0.000 claims 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims 1
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 108700005857 Carnitine palmitoyl transferase 1A deficiency Proteins 0.000 claims 1
- 208000005359 Carnitine palmitoyl transferase 1A deficiency Diseases 0.000 claims 1
- 108700005858 Carnitine palmitoyl transferase 2 deficiency Proteins 0.000 claims 1
- 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 claims 1
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 1
- 208000010354 Coenzyme Q10 deficiency Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000027219 Deficiency disease Diseases 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 102000015782 Electron Transport Complex III Human genes 0.000 claims 1
- 108010024882 Electron Transport Complex III Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 claims 1
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 claims 1
- 101000603761 Homo sapiens Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Proteins 0.000 claims 1
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 206010023126 Jaundice Diseases 0.000 claims 1
- 208000025069 Juvenile Huntington disease Diseases 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 claims 1
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 claims 1
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 claims 1
- 102100021644 Long-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 claims 1
- 208000035172 MERRF Diseases 0.000 claims 1
- 208000014413 Maternally-inherited diabetes and deafness Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010059521 Methylmalonic aciduria Diseases 0.000 claims 1
- 206010059396 Mitochondrial DNA depletion Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000013234 Pearson syndrome Diseases 0.000 claims 1
- 102100038551 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Human genes 0.000 claims 1
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 claims 1
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 claims 1
- 101100240886 Rattus norvegicus Nptx2 gene Proteins 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 206010057430 Retinal injury Diseases 0.000 claims 1
- 206010048327 Supranuclear palsy Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000007950 acidosis Effects 0.000 claims 1
- 208000026545 acidosis disease Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 201000004010 carnitine palmitoyltransferase I deficiency Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 230000008774 maternal effect Effects 0.000 claims 1
- 201000003694 methylmalonic acidemia Diseases 0.000 claims 1
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 claims 1
- 208000015445 pyruvate dehydrogenase deficiency Diseases 0.000 claims 1
- 230000035806 respiratory chain Effects 0.000 claims 1
- 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 1
- 210000001032 spinal nerve Anatomy 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022094160A JP7541546B2 (ja) | 2014-12-16 | 2022-06-10 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462092743P | 2014-12-16 | 2014-12-16 | |
| US62/092,743 | 2014-12-16 | ||
| US201562133276P | 2015-03-13 | 2015-03-13 | |
| US62/133,276 | 2015-03-13 | ||
| JP2020039715A JP7111759B2 (ja) | 2014-12-16 | 2020-03-09 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020039715A Division JP7111759B2 (ja) | 2014-12-16 | 2020-03-09 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022094160A Division JP7541546B2 (ja) | 2014-12-16 | 2022-06-10 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021185199A JP2021185199A (ja) | 2021-12-09 |
| JP2021185199A5 true JP2021185199A5 (https=) | 2022-06-10 |
| JP7277061B2 JP7277061B2 (ja) | 2023-05-18 |
Family
ID=55071223
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532088A Active JP6810692B2 (ja) | 2014-12-16 | 2015-12-16 | （ｒ）−２−ヒドロキシ−２−メチル−４−（２，４，５−トリメチル−３，６−ジオキソシクロヘキサ−１，４−ジエニル）ブタンアミドの多形性形態および非晶質形態 |
| JP2020039715A Active JP7111759B2 (ja) | 2014-12-16 | 2020-03-09 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
| JP2021146086A Active JP7277061B2 (ja) | 2014-12-16 | 2021-09-08 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
| JP2022094160A Active JP7541546B2 (ja) | 2014-12-16 | 2022-06-10 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532088A Active JP6810692B2 (ja) | 2014-12-16 | 2015-12-16 | （ｒ）−２−ヒドロキシ−２−メチル−４−（２，４，５−トリメチル−３，６−ジオキソシクロヘキサ−１，４−ジエニル）ブタンアミドの多形性形態および非晶質形態 |
| JP2020039715A Active JP7111759B2 (ja) | 2014-12-16 | 2020-03-09 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022094160A Active JP7541546B2 (ja) | 2014-12-16 | 2022-06-10 | （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10251847B2 (https=) |
| EP (2) | EP3233786B1 (https=) |
| JP (4) | JP6810692B2 (https=) |
| KR (1) | KR102626895B1 (https=) |
| CN (2) | CN107531616B (https=) |
| AU (3) | AU2015364640B2 (https=) |
| BR (1) | BR112017012988B1 (https=) |
| CA (1) | CA2971252C (https=) |
| DK (1) | DK3233786T3 (https=) |
| ES (1) | ES2912585T3 (https=) |
| HU (1) | HUE058877T2 (https=) |
| IL (1) | IL252953A0 (https=) |
| MX (2) | MX385049B (https=) |
| NZ (1) | NZ733528A (https=) |
| PL (1) | PL3233786T3 (https=) |
| PT (1) | PT3233786T (https=) |
| RU (1) | RU2770091C2 (https=) |
| SG (2) | SG11201704968XA (https=) |
| SI (1) | SI3233786T1 (https=) |
| WO (1) | WO2016100579A1 (https=) |
| ZA (1) | ZA201704639B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2009061744A2 (en) | 2007-11-06 | 2009-05-14 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| CA2741767C (en) | 2008-10-28 | 2017-09-12 | Ptc Therapeutics, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| AU2015364640B2 (en) | 2014-12-16 | 2020-08-13 | Ptc Therapeutics, Inc. | Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| EP3390377B1 (en) | 2015-12-16 | 2026-03-25 | PTC Therapeutics, Inc. | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| KR20210076956A (ko) | 2018-10-17 | 2021-06-24 | 피티씨 테라퓨틱스, 인크. | α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온 |
| TWI886158B (zh) | 2019-10-10 | 2025-06-11 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| KR20220143897A (ko) * | 2020-02-21 | 2022-10-25 | 스미토모 파마 가부시키가이샤 | 광학 분할된 트롤록스 중간체 및 그 제조 방법 |
| PE20240893A1 (es) | 2021-07-08 | 2024-04-24 | Ptc Therapeutics Inc | Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona |
| EP4588473A1 (en) * | 2022-09-12 | 2025-07-23 | PTC Therapeutics, Inc. | Granules for suspension |
| EP4596530A1 (en) * | 2022-09-30 | 2025-08-06 | PTC Therapeutics, Inc. | Oxidative cleavage method of trolox amide |
| WO2025193975A1 (en) | 2024-03-13 | 2025-09-18 | Ptc Therapeutics, Inc. | Formulations for stabilizing dissolution of medicaments |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018799A (en) | 1973-11-19 | 1977-04-19 | Hoffmann-La Roche Inc. | Antioxidant chroman compounds |
| US4026907A (en) | 1973-11-19 | 1977-05-31 | Hoffmann-La Roche Inc. | Antioxidant chroman compounds |
| JPS5640651A (en) | 1979-09-12 | 1981-04-16 | Takeda Chem Ind Ltd | Quinone compound and its preparation |
| US5272180A (en) | 1987-07-29 | 1993-12-21 | Takeda Chemical Industries, Ltd. | Cell proliferation inhibitor |
| US5348973A (en) | 1990-10-09 | 1994-09-20 | Rhone-Poulenc Chimie | Resolution of hydroxychroman-2-carboxylic acid esters by enantiomeric hydrolysis |
| US6150402A (en) | 1994-08-15 | 2000-11-21 | Loma Linda University Medical Center | Natriuretic compounds |
| SK282144B6 (sk) | 1994-12-28 | 2001-11-06 | Janssen Pharmaceutica N. V. | Liečivo na terapeutické a profylaktické ošetrenie degeneratívnych chorôb vaskulárneho systému a nervovej sústavy, ktoré súvisia s oxidačným stresom |
| AU6709896A (en) | 1995-08-21 | 1997-03-12 | Takeda Chemical Industries Ltd. | Quinone compound, its production and use |
| US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
| US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| DE69712888D1 (de) | 1996-07-11 | 2002-07-04 | Takeda Chemical Industries Ltd | ZUSAMMENSTELLUNGEN DIE beta-AMYLOID PROTEIN BEDINGTE ZYTOTOXIZITÄT VERHINDERN |
| US5821247A (en) | 1996-09-19 | 1998-10-13 | Japan Energy Corporation | Hydroquinone derivative and pharmaceutical use thereof |
| JP3093170B2 (ja) * | 1996-09-19 | 2000-10-03 | 株式会社ジャパンエナジー | ヒドロキノン誘導体及びその医薬用途 |
| JP3913329B2 (ja) * | 1997-09-11 | 2007-05-09 | 株式会社クラレ | （±）−クロマンカルボン酸の光学分割法 |
| FR2783519B1 (fr) | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| WO2000078296A2 (en) | 1999-06-17 | 2000-12-28 | Basf Aktiengesellschaft | Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders |
| US6426362B1 (en) | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
| US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| WO2002012221A1 (en) | 2000-08-03 | 2002-02-14 | Kuraray Co., Ltd. | Method for optical resolution of (±)-6-hydroxy-2,5,7,8-tetramethylcoumarone-2-carboxylic acid |
| US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
| WO2002047680A2 (en) | 2000-12-15 | 2002-06-20 | Galileo Laboratories, Inc. | Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
| US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
| NZ513547A (en) | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
| WO2003015494A2 (en) | 2001-08-21 | 2003-02-27 | Galileo Pharmaceuticals, Inc. | Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| AU2002352726A1 (en) | 2001-11-15 | 2003-06-10 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
| US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
| US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| US7078541B2 (en) | 2002-02-07 | 2006-07-18 | Galileo Pharmaceuticals, Inc. | Benzofuran derivatives |
| GB0204232D0 (en) | 2002-02-22 | 2002-04-10 | Isis Innovation | Assay |
| DE60211875T2 (de) | 2002-07-01 | 2006-10-26 | Santhera Pharmaceuticals (Schweiz) Ag | Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia |
| JP4599292B2 (ja) | 2002-10-30 | 2010-12-15 | エジソン ファーマシューティカルズ， インコーポレイテッド | 物理的−化学的特性に基づく治療用化合物の同定 |
| EP1454627A1 (en) | 2003-03-06 | 2004-09-08 | MyoContract Ltd. | Alpha-Keto carbonyl calpain inhibitors |
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| FR2875803B1 (fr) | 2004-09-24 | 2006-11-24 | Catalys Sarl | Preparation de composes phenol-amides a proprietes antioxydantes |
| EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| CA2622523C (en) | 2005-09-15 | 2014-02-18 | Edison Pharmaceuticals, Inc. | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2007095630A2 (en) | 2006-02-15 | 2007-08-23 | The Regents Of The University Of California | New ubiquinone analogs and methods of use |
| US9278085B2 (en) | 2006-02-22 | 2016-03-08 | Edison Pharmaceuticals, Inc. | Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP2088144B1 (en) * | 2006-10-26 | 2011-12-28 | Mitsubishi Gas Chemical Company, Inc. | Method of producing s-(-)-6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid |
| WO2008086025A2 (en) | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
| WO2009061744A2 (en) * | 2007-11-06 | 2009-05-14 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
| WO2009088572A2 (en) | 2008-01-07 | 2009-07-16 | Centocor, Inc. | Method of treating erythropoietin hyporesponsive anemias |
| EA023618B1 (ru) | 2008-01-08 | 2016-06-30 | Эдисон Фармасьютикалз, Инк. | Производные (гет)арил-п-хинона для лечения митохондриальных болезней |
| EP2262519A4 (en) | 2008-03-05 | 2011-03-23 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCING DISORDERS WITH REDOXACTIVE THERAPEUTICS |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| CA2723621A1 (en) | 2008-05-15 | 2009-11-19 | Edison Pharmaceuticals, Inc | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
| WO2009143268A2 (en) | 2008-05-22 | 2009-11-26 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| JP5266875B2 (ja) | 2008-05-23 | 2013-08-21 | 三菱瓦斯化学株式会社 | 有機カルボン酸エステルからの光学活性有機カルボン酸の製造方法 |
| WO2009158348A1 (en) | 2008-06-25 | 2009-12-30 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| WO2010005989A1 (en) | 2008-07-09 | 2010-01-14 | Edison Pharmaceuticals, Inc. | Dermatological compositions with anti-aging and skin even-toning properties |
| US20100029784A1 (en) | 2008-07-30 | 2010-02-04 | Hinman Andrew W | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties |
| WO2010014758A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| CA2741767C (en) | 2008-10-28 | 2017-09-12 | Ptc Therapeutics, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| PL2424495T3 (pl) | 2009-04-28 | 2018-06-29 | Bioelectron Technology Corporation | Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu |
| JP2012525397A (ja) | 2009-04-28 | 2012-10-22 | エジソン ファーマシューティカルズ， インコーポレイテッド | 眼科疾患を治療するためのトコトリエノールキノンの製剤 |
| EP2424360A4 (en) | 2009-04-28 | 2012-10-03 | Ampere Life Sciences Inc | TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES |
| EP2609921A1 (en) | 2009-06-25 | 2013-07-03 | Ampere Life Sciences, Inc. | Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts |
| DK2470168T3 (en) | 2009-08-26 | 2018-05-07 | Bioelectron Tech Corp | PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM |
| WO2011041452A2 (en) | 2009-10-01 | 2011-04-07 | Ampere Life Sciences, Inc. | Mouse model for identifying compounds for the treatment of oxidative stress |
| US20110172312A1 (en) | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| US8464722B2 (en) | 2010-03-04 | 2013-06-18 | Medline Industries, Inc. | Folded telescopic equipment drape and method of folding and using the same |
| SG184787A1 (en) | 2010-03-09 | 2012-11-29 | Edison Pharmaceuticals Inc | Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
| WO2011113018A1 (en) | 2010-03-12 | 2011-09-15 | Ampere Life Sciences, Inc. | Measurement and control of biological time |
| AU2011238525A1 (en) | 2010-04-06 | 2012-11-08 | Edison Pharmaceuticals, Inc. | Treatment of Ataxia Telangiectasia |
| CA2797581A1 (en) | 2010-04-27 | 2011-11-03 | Edison Pharmaceuticals, Inc. | Formulations of quinones for the treatment of ophthalmic diseases |
| US20120101169A1 (en) | 2010-07-14 | 2012-04-26 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
| EP2601168A4 (en) | 2010-08-06 | 2013-12-04 | Ampere Life Sciences Inc | TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K |
| EA201300215A1 (ru) | 2010-08-06 | 2013-07-30 | Эдисон Фармасьютикалз, Инк. | Лечение митохондриальных болезней нафтохинонами |
| WO2012068552A1 (en) | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| WO2012154613A1 (en) | 2011-05-06 | 2012-11-15 | Edison Pharmaceuticals, Inc. | Improved process for the preparation of d-alpha-tocotrienol from natural extracts |
| WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| WO2013006736A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
| US20150057363A1 (en) | 2011-07-06 | 2015-02-26 | Guy M. Miller | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| EA031098B1 (ru) | 2013-03-08 | 2018-11-30 | Юнилевер Н.В. | Соединения резорцина для дерматологического применения |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| AU2014273891A1 (en) | 2013-05-31 | 2015-12-24 | Bioelectron Technology Corporation | Carboxylic acid derivatives for treatment of oxidative stress disorders |
| US20180002247A1 (en) | 2014-12-16 | 2018-01-04 | Bioelectron Technology Corporation | Methods for chiral resolution of trolox |
| AU2015364640B2 (en) | 2014-12-16 | 2020-08-13 | Ptc Therapeutics, Inc. | Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| WO2016114860A1 (en) | 2015-01-12 | 2016-07-21 | Edison Pharmaceuticals, Inc. | Quinones for protection against radiation exposure |
| EP3390377B1 (en) | 2015-12-16 | 2026-03-25 | PTC Therapeutics, Inc. | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| WO2017123823A1 (en) | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Alkyl-, acyl-, urea-, and aza-uracil sulfide:quinone oxidoreductase inhibitors |
| JP2019501974A (ja) | 2016-01-12 | 2019-01-24 | バイオエレクトロン テクノロジー コーポレイション | チオスルフェートレベルを増加させるためのまたは硫化水素レベルを低下させるためのトコフェロールキノン誘導体およびトコトリエノールキノン誘導体 |
| WO2018081644A1 (en) | 2016-10-28 | 2018-05-03 | Bioelectron Technology Corporation | Methods of analyzing p-hydroquinone levels and ratios |
| WO2018093957A1 (en) | 2016-11-15 | 2018-05-24 | Bioelectron Technology Corporation | 2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof cross reference to related applications |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| WO2018129411A1 (en) | 2017-01-06 | 2018-07-12 | Bioelectron Technology Corporation | Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders |
| WO2018191732A1 (en) | 2017-04-14 | 2018-10-18 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
| US20180333389A1 (en) | 2017-04-14 | 2018-11-22 | Bioelectron Technology Corporation | Vitamin e compositions and methods of use therefor |
-
2015
- 2015-12-16 AU AU2015364640A patent/AU2015364640B2/en active Active
- 2015-12-16 US US15/536,603 patent/US10251847B2/en active Active
- 2015-12-16 EP EP15820968.4A patent/EP3233786B1/en active Active
- 2015-12-16 SI SI201531829T patent/SI3233786T1/sl unknown
- 2015-12-16 BR BR112017012988-4A patent/BR112017012988B1/pt active IP Right Grant
- 2015-12-16 RU RU2017124714A patent/RU2770091C2/ru active
- 2015-12-16 JP JP2017532088A patent/JP6810692B2/ja active Active
- 2015-12-16 SG SG11201704968XA patent/SG11201704968XA/en unknown
- 2015-12-16 PT PT158209684T patent/PT3233786T/pt unknown
- 2015-12-16 PL PL15820968T patent/PL3233786T3/pl unknown
- 2015-12-16 MX MX2017008063A patent/MX385049B/es unknown
- 2015-12-16 DK DK15820968.4T patent/DK3233786T3/da active
- 2015-12-16 WO PCT/US2015/066211 patent/WO2016100579A1/en not_active Ceased
- 2015-12-16 NZ NZ733528A patent/NZ733528A/en unknown
- 2015-12-16 SG SG10202003299PA patent/SG10202003299PA/en unknown
- 2015-12-16 EP EP22155382.9A patent/EP4059922A1/en active Pending
- 2015-12-16 ES ES15820968T patent/ES2912585T3/es active Active
- 2015-12-16 KR KR1020177019399A patent/KR102626895B1/ko active Active
- 2015-12-16 CN CN201580076205.0A patent/CN107531616B/zh active Active
- 2015-12-16 HU HUE15820968A patent/HUE058877T2/hu unknown
- 2015-12-16 CN CN202210321539.1A patent/CN114702406B/zh active Active
- 2015-12-16 CA CA2971252A patent/CA2971252C/en active Active
-
2017
- 2017-06-15 IL IL252953A patent/IL252953A0/en unknown
- 2017-06-16 MX MX2021009340A patent/MX2021009340A/es unknown
- 2017-07-10 ZA ZA2017/04639A patent/ZA201704639B/en unknown
-
2019
- 2019-03-14 US US16/354,070 patent/US10751302B2/en active Active
-
2020
- 2020-03-09 JP JP2020039715A patent/JP7111759B2/ja active Active
- 2020-07-01 US US16/919,044 patent/US11304914B2/en active Active
- 2020-07-24 AU AU2020207880A patent/AU2020207880C1/en active Active
-
2021
- 2021-09-08 JP JP2021146086A patent/JP7277061B2/ja active Active
-
2022
- 2022-03-10 US US17/692,133 patent/US11938101B2/en active Active
- 2022-05-03 AU AU2022202949A patent/AU2022202949B2/en active Active
- 2022-06-10 JP JP2022094160A patent/JP7541546B2/ja active Active
-
2023
- 2023-07-05 US US18/218,575 patent/US20230364029A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021185199A5 (https=) | ||
| JP2018500326A5 (https=) | ||
| RU2017124714A (ru) | Полиморфные и аморфные (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида | |
| JP2022017447A5 (https=) | ||
| TW202210075A (zh) | 治療組合物 | |
| JP2016514697A5 (https=) | ||
| JP2016515527A5 (https=) | ||
| US20210113590A1 (en) | Compositions and methods for treating cns disorders | |
| JP2016520621A5 (https=) | ||
| US9670170B2 (en) | Resorufin derivatives for treatment of oxidative stress disorders | |
| JP2016515526A5 (https=) | ||
| CN115551874A (zh) | 神经活性类固醇及其使用方法 | |
| WO2014039917A1 (en) | Benzoquinone derivatives for treating oxidative stress disorders | |
| US9670175B2 (en) | Protected succinates for enhancing mitochondrial ATP-production | |
| EP3457851A1 (en) | Derivatives of sobetirome | |
| RU2009136911A (ru) | Соединения, представляющие собой стиролильные производные, для лечения офтальмических заболеваний и расстройств | |
| BR112022014749A2 (pt) | Composto tricíclico fundido e uso medicinal do mesmo | |
| EP2814479B1 (en) | Methods of treating amyotrophic lateral sclerosis | |
| JP2021527049A5 (https=) | ||
| EP3813794A1 (en) | Ophthalmic compositions and methods for the treatment of eye disorders | |
| US20240122876A1 (en) | Compositions and methods for the treatment of ocular disorders | |
| CN118986972A (zh) | Kv7通道激活剂的使用方法 | |
| US11731938B2 (en) | Ultra short acting anti-arrhythmic agents | |
| IL165787A (en) | Derivatives 8,6-Dioxa-3-Aza-Bicyclo [3.2.1] Octane-2-On for use in tomographic imaging and pharmaceutical preparations containing them | |
| JP2024519046A (ja) | Ｋｌ１３３３の医薬用途 |